Teriparatide may lower fracture risk in women with osteoporosis
Postmenopausal women with severe osteoporosis could have a lower risk of new fractures when treated with a drug called teriparatide compared with risedronate, according to new findings.
Experts looked at data from 1,360 women (average age, 72 years) with osteoporosis. Half were given a daily injection of teriparatide plus an oral weekly sham drug. The other half were given oral risedronate once a week plus daily injections of a sham drug for up to two years.
The results revealed that women in the teriparatide group had a lower risk of new vertebral fractures compared with the risedronate group.
To read more research news about osteoporosis click here.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.